Serina Therapeutics Inc. (SER) Options Positioning, Max Pain & Unusual Sweeps

The per the Roarable RQD rating, SER scores 31 on a 100-point scale, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 8 / 20. The rating cites ROIC of -35% and an FCF yield of 0%. For an investor, this indicates the business is not currently generating returns on capital or free cash flow available to shareholders.
• Whale 13F Flow: 5 / 20. Described as reflecting institutional accumulation and options positioning. The low score suggests limited institutional support in the source-based assessment.
• Insider Conviction: 3 / 20. Based on SEC Form 4 and Congressional PTR cluster flow. This is the lowest pillar and indicates weak insider conviction signals.
• Macro Regime Fit: 7 / 20. Reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is rated as moving in line with the market, offering no defensive characteristic under this framework.
• Forensic Balance Sheet: 8 / 20. Per the rating, Altman Z is 2.5, Piotroski F is 3 of 9, and Debt/Equity is 0.5. The Piotroski reading is weak, and the balance sheet is scored as a forensic concern.

Taken together, the rating's upside drivers are limited to the sector-sensitivity and market-beta characteristics, while the principal valuation tradeoff is that the company reports negative returns on capital and no free-cash-flow yield. The sub-20 scores in every pillar mean no single factor offsets the others, and the rating's verdict is to avoid.

Serina Therapeutics Inc. is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is listed on the NYSE under the ticker SER. The source data does not describe its products, customers, or revenue model.

Per the SEC financials, revenue fell from $3.2M in FY 2023 to $0.1M in each of FY 2024 and FY 2025, while operating losses widened from $-3.1M to $-24.0M over the same period. Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3 of 9, with Debt/Equity of 0.5. Cash declined from $3.7M in FY 2024 to $3.1M in FY 2025.

The recent news wire contains six items, all tagged to SER. Two are flagged RED or YELLOW as follows:

• Risk Watch (RED): An item from 12 hours before the data timestamp, headlined as Serina Therapeutics (SER) slipping 3% to $1.94 toward lower support, is categorized under risk watch.
• Market Wire (YELLOW): Five items are categorized under market wire, comprising a general stock-price and analysis report (debelegger.nl), an estimates report (TradingView), a seasonal returns chart for aTyr Pharma (ATYR) on Yahoo Finance Canada, a McClellan Oscillator-related price item (siam.in), and a seasonal returns chart for Psyence Biomedical (PBM) on Yahoo Finance Canada.

The news items are generic market-wire content. None describes a specific clinical, regulatory, financing, or partnership event. The Butterfly Supply-Chain Graph reports no proprietary signals.

• What products or clinical programs does Serina Therapeutics develop, and what is their development stage?
• What drove the decline in reported revenue from $3.2M in FY 2023 to $0.1M in FY 2024 and FY 2025?
• What is the company's current cash runway given $3.1M in cash against a FY 2025 FCF of $-18.0M?
• What is the company's debt position, given that debt is reported as N/A for every period?
• What EPS, P/E, and EV/EBITDA figures apply, given that these are unavailable in the source data?